Trial Profile
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 27 Jan 2024 Results in for veterans with de novo oligometastatic prostate cancer, presented at the 2024 Genitourinary Cancers Symposium
- 25 Jul 2023 Planned End Date changed from 30 Jun 2023 to 31 Mar 2024.
- 25 Jul 2023 Planned primary completion date changed from 30 Sep 2022 to 31 Mar 2024.